ProCE Banner Activity

FAQs: Fine-tuning Contemporary Treatment for Patients With CLL/SLL

Clinical Thought

In this commentary, expert faculty address frequently asked questions to help fine-tune current optimal treatment of patients with CLL/SLL based on the latest data.

Released: July 21, 2023

Share

Faculty

Brian Hill

Brian Hill, MD, PhD

Director, Lymphoid Malignancies Program
Staff Physician, Department of Hematology and Medical Oncology
Taussig Cancer Institute
Cleveland Clinic
Cleveland, Ohio

Jeremy S. Abramson

Jeremy S. Abramson, MD, MMSc

Director, Center for Lymphoma
Massachusetts General Hospital
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Farrukh Awan

Farrukh Awan, MD, MS, MBA

Professor of Internal Medicine
Director of Lymphoid Malignancies Program
Harold C. Simmons Comprehensive Cancer Center
University of Texas Southwestern Medical Center
Dallas, Texas

Provided by

Provided by the National Comprehensive Cancer Network, in partnership with Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca, BeiGene, and Lilly.

Supported by independent educational grants from Merck & Co., Inc., Rahway, NJ, USA, and Pharmacyclics, an AbbVie Company and Janssen Biotech, Inc.

AstraZeneca

BeiGene, Ltd.

Janssen Biotech, Inc.

Lilly

Merck Sharp & Dohme Corp.

Pharmacyclics LLC, an AbbVie Company

Partners

Clinical Care Options, LLC

ProCE Banner

Program Director Disclosure

Program Director

Brian Hill, MD, PhD

Director, Lymphoid Malignancies Program
Staff Physician, Department of Hematology and Medical Oncology
Taussig Cancer Institute
Cleveland Clinic
Cleveland, Ohio

Brian Hill, MD, PhD: consultant/advisor/speaker: AbbVie, AstraZeneca, Beigene, Bristol-Myers Squibb, Genentech, Kite Pharma, Novartis.

Faculty Disclosure

Primary Author

Jeremy S. Abramson, MD, MMSc

Director, Center for Lymphoma
Massachusetts General Hospital
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Jeremy Abramson, MD, MMSc: consultant/advisor/speaker: AbbVie, AstraZeneca, BeiGene, Bristol-Myers Squibb, Caribou Biosciences, Cellectar, Century Therapeutics, Epizyme, Genentech, Genmab, Incyte, Interius, Janssen, Kite Pharma, Kymera, Lilly, MorphoSys, Mustang Bio, Ono Pharma, Regeneron, Takeda; researcher: Bristol-Myers Squibb, Cellectis, Merck, Mustang Bio, Seattle Genetics.

Farrukh Awan, MD, MS, MBA

Professor of Internal Medicine
Director of Lymphoid Malignancies Program
Harold C. Simmons Comprehensive Cancer Center
University of Texas Southwestern Medical Center
Dallas, Texas

Farrukh Awan, MD: consultant/advisor/speaker: AbbVie, Adaptive Biotechnologies, ADCT Therapeutics, AstraZeneca, BeiGene, Bristol Myers Squibb, Cardinal Health, Caribou Biosciences, Celgene, Cellecter Biosciences, Dava Oncology, Epizyme, Genentech, Genmab, Gilead Sciences, Incyte, Janssen, Johnson & Johnson, Karyopharm, Kite, MEI Pharma, Merck, Pharmacyclics, and Verastem; researcher: Pharmacyclics.